UK Gives Eligible Late-onset Pompe Patients Early Access to AT-GAA

UK Gives Eligible Late-onset Pompe Patients Early Access to AT-GAA

296730

UK Gives Eligible Late-onset Pompe Patients Early Access to AT-GAA

AT-GAA, an investigational therapy by Amicus Therapeutics for late-onset Pompe disease, will be available to select patients in the U.K. through an early access program before its potential regulatory approval. Eligible patients are adults who have received the enzyme replacement therapy (ERT) alglucosidase alfa — the current standard Pompe treatment marketed as Myozyme in Europe and Lumizyme in the U.S. — for at least two years. The Early Access to Medicines Scheme in the U.K.…

You must be logged in to read/download the full post.